Medical Articles

Cannabinoids for neuropathic pain.

The endocannabinoid system has been elucidated over the last several years, demonstrating a significant interface with pain homeostasis. Exogenous cannabinoids have been demonstrated to be effective in a range of experimental neuropathic pain models, and there is mounting evidence for therapeutic use in human neuropathic pain conditions

View Article
Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence.

Gold standard clinical trials are limited; however, some studies have thus far shown evidence to support the use of cannabinoids for some cancer, neuropathic, spasticity, acute pain, and chronic pain conditions.

View Article
Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials.

An updated systematic review of randomized controlled trials examining cannabinoids in the treatment of chronic non-cancer pain demonstrated a significant analgesic effect. Several trials also demonstrated improvement in secondary outcomes (e.g., sleep, muscle stiffness and spasticity).

View Article
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine in the treatment of pain caused by rheumatoid arthritis

This study showed a significant analgesic effect was observed and disease activity was significantly suppressed following cannabis treatment.

View Article
Cannabinoids in the management of difficult to treat pain.

Numerous randomized clinical trials have demonstrated safety and efficacy for cannabis-based medicine in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.

View Article
CBD extract and THC extract in patients with intractable cancer-related pain.

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. This study shows that THC:CBD extract is efficacious for relief of pain in patients with advanced cancer pain not fully relieved by strong opioids.

View Article
Efficacy of Cannabis-based Medicine on Painful Diabetic Neuropathy.

This small, short-term, placebo-controlled trial of cannabis demonstrated a dose-dependent reduction in diabetic peripheral neuropathy pain in patients with treatment-refractory pain. This adds preliminary evidence to support further research on the efficacy of the cannabinoids in neuropathic pain.

View Article
Cannabis for the Management of Pain: Assessment of Safety Study.

Quality-controlled herbal cannabis, when used by patients with experience of cannabis use as part of a monitored treatment program over 1 year, appears to have a reasonable safety profile.

View Article
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.

Efficacy of THC-CBD oromucosal spray has been proven in randomized, controlled clinical studies and its effectiveness confirmed in observational studies. It shows alleviation of symptoms together with improvement of daily activities and improvement in quality of life for patients. About 80% of patients suffer from MS-associated spasticity or spasticity associated symptoms during their MS disease […]

View Article
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.

Cannabis-based medicine can be a useful and safe option for patients with MS with moderate to severe spasticity resistant to common anti-spastic drugs.

View Article
Multiple sclerosis and extract of cannabis.

The study demonstrates the superiority of oral cannabis extract over placebo in the treatment of muscle stiffness in MS. Adverse events in participants treated with oral cannabis extract were consistent with the known side effects of cannabinoids and no new safety concerns were observed.

View Article
Cannabinoids in the management of spasticity associated with multiple sclerosis.

An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of MS, including spasticity and pain. We report on the current treatments used to control MS symptoms and the most recent clinical studies based on cannabinoid treatments.

View Article
Cannabinoids in multiple sclerosis safety and efficacy data for 12 months follow up.

This study data provides limited evidence for a longer term treatment effect of cannabinoids.

View Article
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis.

Level A Evidence supports the recommendation that clinicians may offer oral cannabis extract for spasticity symptoms and pain.

View Article
Antiepileptic Efficacy Study of Cannabis extract in Children and Young Adults With Dravet Syndrome.

A preliminary report from this open-label study noted that among 137 patients who had received at least 12 weeks of treatment, the median reduction in the number of seizures was 54%.

View Article
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

Our findings suggest that cannabidiol might reduce seizure frequency and might have an adequate safety profile in children and young adults with highly treatment-resistant epilepsy. Randomized controlled trials are warranted to characterize the safety profile and true efficacy of this compound.

View Article
Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.

In this report, 57% of parents reported improvement in seizure control and 33% reported a >50% reduction in seizures when utilizing oral cannabis extracts.

View Article
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regards to their relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology and data from studies with animal models and human […]

View Article
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Parents report a high rate of success in reducing seizure frequency with this treatment. Cannabidiol-enriched cannabis appears to be behaviorally well tolerated with some positive side effects not commonly associated with other treatments. The overall positive results on seizure control in a medically refractory group of childhood epilepsies suggest further studies of cannabidiol are warranted.

View Article
Cannabinoids for Medical Use. A Systematic Review and Meta-analysis.

There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. Furthermore, there was some evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.

View Article
Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders.

Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Oral cannabis extract is effective for reducing patient-centered measures of spasticity in patients with multiple sclerosis.

View Article
Cannabinoids in the Treatment of Epilepsy.

This New England Journal of Medicine study found that the pharmacologic and biochemical features of cannabinoids make them candidates for anti-seizure medications.

View Article
Study: THC Stimulates Toxic Plaque Removal in the Brain, Blocks Inflammation, Finds Study.

A study published last month in Nature Partner Journals found

View Article
Study: Heart Attack Patients with History of Cannabis Use Less Likely to Die During Hospitalization.

Those with a history of cannabis use who suffer from a heart attack are less likely to die during hospitalization, according to a study presented in April at the annual meeting of the American College of Cardiology.

View Article
Study: Cannabis Use Can Help Treat Symptoms of Bipolar Disorder.

Inhaling cannabis can help treat the symptoms of bipolar disorder without any negative cognitive impact, according to a study published in the journal PLoS ONE.

View Article
Study: Cannabinoids May Prevent Cartilage Breakdown in those with Osteoarthritis

A study published in the April issue of the journal Molecular Medicine Reports, and published online by the U.S. National Institute of Health, found that cannabinoids may prevent cartilage breakdown in those with osteoarthritis.

View Article
Study: Recent Cannabis Use Linked to Better Outcomes for Brain Injury Patients.

The recent use of cannabis is associated with improved outcomes in patients hospitalized with intracerebral hemorrhaging (ICH aka bleeding in the brain), according to data published online ahead of print in the journal Cerebrovascular Diseases.

View Article
Study: Alcohol Use Increases Aggression, Cannabis Use Decreases It.

A study published in the most recent issue of the journal Psychopharmacology has found that alcohol significantly increases aggression while cannabis significantly decreases it. The study was a random controlled trial, typically refereed to as the “gold standard” for research studies.

View Article
Study: Legalizing Medical Cannabis Decreases Workplace Absences.

According to a study published in the journal Health Economics, the legalization of medical cannabis is associated with a decrease in the total number of workplace absences that are caused by sickness.

View Article
Study: CBD Oil ‘Highly Promising’ as Treatment for Pediatric Epilepsy.

The administration of cannabis oil extracts high in cannabidiol reduces seizure frequency in children with intractable epilepsy, according to clinical data published by the journal Seizure.

View Article
Study: Cannabis Use Not Predictive Of Lower IQ, Poorer Educational Performance.

Adolescent cannabis use is not associated with lower IQ or poorer educational performance – even once adjustments are made for potential confounders such as cigarette smoking -a ccording to a study published in the Journal of Psychopharmacology.

View Article
Study: Cannabinoids Can Inhibit Growth of Carcinoma Cancer Cells, Program them to Die.

A study published in May by the U.S. National Institute of Health found that cannabinoids can inhibit the growth of carcinoma cancer cells, and can essentially program currently active cancer cells to die.

View Article